Literature DB >> 23746688

Impact of iodine delivery rate with varying flow rates on image quality in dual-energy CT of patients with suspected pulmonary embolism.

Jan Hansmann1, Christian Fink, Gregor Jost, Hubertus Pietsch, Mathias Meyer, John W Nance, Uwe J Schoepf, Ulrike I Attenberger, Stefan O Schoenberg, Thomas Henzler.   

Abstract

RATIONALE AND
OBJECTIVES: To prospectively compare four contrast material injection protocols for dual-energy computed tomography (CT) pulmonary angiography (DE-CTPA) in patients with suspected pulmonary embolism (PE).
MATERIALS AND METHODS: One hundred twenty consecutive patients were randomized to contrast material injection protocols defined by different iodine concentrations and iodine delivery rates (IDRs): (A) 80 mL iopromide 370/4 mL/sec = IDR 1.4 gI/sec; (B) 80 mL iopromide 370 at 3 mL/sec = IDR 1.1 gI/sec; (C) 98 mL iopromide 300 at 4.9 mL/sec = IDR 1.4 gI/sec; and (D) 98 mL iopromide 300 at 3.7 mL/sec = IDR 1.1 gI/sec. Attenuation values were measured in the inflow tract (subclavian vein-superior vena cava-right atrium), target tract (right ventricle-pulmonary trunk-pulmonary arteries), and outflow tract (left atrium-left ventricle-ascending aorta). Two readers assessed subjective image quality of CTPA images and iodine perfusion maps. The number of artifacts due to hyperdense contrast material on iodine perfusion maps was recorded.
RESULTS: Target tract attenuation was highest for protocol A with 374 ± 98 Hounsfield units (HU) (highly concentrated contrast material/high IDR). This was significant compared to protocols B and D (P = .0118, P = .0427) but not compared to protocol C (P = .3395). No significant difference in target tract attenuation was found between protocols B (309 ± 80 HU), protocol C (352 ± 119 HU), and D (325 ± 74 HU). CTPA and iodine perfusion map image quality for protocol A was rated significantly higher compared to all other protocols (median score = 5/4; P < .0001 for both) with moderate interreader agreement (κ = 0.58/0.47). Protocols A and B displayed increased artifacts on iodine perfusion maps compared to protocols C and D (3 versus 2).
CONCLUSION: Despite increased artifacts on iodine perfusion maps, highly concentrated iodinated contrast material combined with high flow rates provides improved diagnostic image quality and has the highest target-tract attenuation for DE-CTPA protocols.
Copyright © 2013 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dual-energy CT; iodine delivery rate; pulmonary embolism; pulmonary perfusion

Mesh:

Substances:

Year:  2013        PMID: 23746688     DOI: 10.1016/j.acra.2013.02.013

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  5 in total

1.  Individually tailored contrast enhancement in CT pulmonary angiography.

Authors:  Babs M F Hendriks; Madeleine Kok; Casper Mihl; Sebastiaan C A M Bekkers; Joachim E Wildberger; Marco Das
Journal:  Br J Radiol       Date:  2016-01-22       Impact factor: 3.039

Review 2.  Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities.

Authors:  Wouter van Elmpt; Catharina M L Zegers; Marco Das; Dirk De Ruysscher
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

3.  Performance of Centargo: A Novel Piston-Based Injection System for High Throughput in CE CT.

Authors:  Corey A Kemper; Casper Mihl; Bibi Martens; Michael C McDermott; Babs M F Hendriks
Journal:  Med Devices (Auckl)       Date:  2022-04-05

Review 4.  Vascular CT and MRI: a practical guide to imaging protocols.

Authors:  D J Murphy; A Aghayev; M L Steigner
Journal:  Insights Imaging       Date:  2018-03-14

5.  Dual-energy CT angiography in suspected pulmonary embolism: influence of injection protocols on image quality and perfused blood volume.

Authors:  Aleksander Kosmala; Philipp Gruschwitz; Simon Veldhoen; Andreas Max Weng; Bernhard Krauss; Thorsten Alexander Bley; Bernhard Petritsch
Journal:  Int J Cardiovasc Imaging       Date:  2020-06-06       Impact factor: 2.357

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.